Screening of Fabry Disease in Patients With Left Ventricular Hypertrophy Detected in Echocardiography
Completed
- Conditions
- Left Ventricular Hypertrophy
- Registration Number
- NCT02221141
- Lead Sponsor
- Laurence Gabriel
- Brief Summary
The purpose of this study is to determine the prevalence in Belgium of Fabry disease in patients with unexplained hypertrophic cardiomyopathy measured by echocardiography and to determine in Fabry patients which was the most frequently initial symptom.
Actually the early diagnosis is important because a treatment exists that can prevent future complications.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
- unexplained left ventricular hypertrophy
Exclusion Criteria
- isolated septal hypertrophy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of patients with left ventricular hypertrophy who have Fabry Disease mutation 1 day
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
CHU Dinant-Godinne
🇧🇪Yvoir, Belgium